JMP Securities lowered the firm’s price target on OrthoPediatrics to $50 from $60 and keeps an Outperform rating on the shares. Top-line results were just shy of consensus estimates, and while management highlighted that some headwinds persisted in the children’s hospital environment, it noted some improvement in the overall landscape, and the company continues to drive revenue, primarily through market share gains, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KIDS:
- OrthoPediatrics Corp. Announces Launch of Specialty Bracing Division
- OrthoPediatrics Corp. to Host Educational and Networking Events at 19th Annual International Pediatric Orthopaedic Symposium (IPOS)
- OrthoPediatrics backs FY23 revenue view $148M-$151M, consensus $149.17M
- OrthoPediatrics reports Q3 adjusted EPS (13c), consensus (22c)
- OrthoPediatrics Corp. Reports Third Quarter 2023 Financial Results
